KR102603153B1 - C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도 - Google Patents

C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도 Download PDF

Info

Publication number
KR102603153B1
KR102603153B1 KR1020197034070A KR20197034070A KR102603153B1 KR 102603153 B1 KR102603153 B1 KR 102603153B1 KR 1020197034070 A KR1020197034070 A KR 1020197034070A KR 20197034070 A KR20197034070 A KR 20197034070A KR 102603153 B1 KR102603153 B1 KR 102603153B1
Authority
KR
South Korea
Prior art keywords
amino
acetamide
triazol
compound
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197034070A
Other languages
English (en)
Korean (ko)
Other versions
KR20190141203A (ko
Inventor
튜더 그레큐
제이슨 그랜트 케틀
마틴 존 팩커
스튜어트 에릭 피어슨
제임스 마이클 스미스
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20190141203A publication Critical patent/KR20190141203A/ko
Application granted granted Critical
Publication of KR102603153B1 publication Critical patent/KR102603153B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197034070A 2017-04-27 2018-04-26 C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도 Active KR102603153B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490859P 2017-04-27 2017-04-27
US62/490,859 2017-04-27
PCT/EP2018/060798 WO2018197642A1 (en) 2017-04-27 2018-04-26 C5-anilinoquinazoline compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
KR20190141203A KR20190141203A (ko) 2019-12-23
KR102603153B1 true KR102603153B1 (ko) 2023-11-15

Family

ID=62091877

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197034070A Active KR102603153B1 (ko) 2017-04-27 2018-04-26 C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도

Country Status (13)

Country Link
US (2) US10273227B2 (enExample)
EP (1) EP3615522B1 (enExample)
JP (1) JP7128204B2 (enExample)
KR (1) KR102603153B1 (enExample)
CN (1) CN110573505B (enExample)
AR (1) AR111494A1 (enExample)
AU (1) AU2018259078B2 (enExample)
CA (1) CA3059283A1 (enExample)
ES (1) ES2888298T3 (enExample)
MX (1) MX389244B (enExample)
RU (1) RU2769694C2 (enExample)
TW (1) TWI774758B (enExample)
WO (1) WO2018197642A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018259078B2 (en) * 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
US20210380685A1 (en) * 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis
AR117788A1 (es) * 2019-01-14 2021-08-25 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
US20240034788A1 (en) * 2020-08-20 2024-02-01 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
WO2022053657A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
JP2023542290A (ja) 2020-09-10 2023-10-06 ジェンマブ エー／エス 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
KR20230064560A (ko) * 2021-10-29 2023-05-10 보로노이바이오 주식회사 퀴나졸린 유도체 화합물 및 이의 용도
MX2024007044A (es) * 2021-12-09 2024-09-04 Deciphera Pharmaceuticals Llc Compuestos heterociclicos como inhibidores de kit quinasa.
US20250275978A1 (en) * 2024-03-04 2025-09-04 Cardiff Oncology, Inc. Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509499A (ja) 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ キナゾリン誘導体およびそれらの医薬品としての使用
US20060178382A1 (en) 2003-06-17 2006-08-10 Astrazeneca Ab Chinazoline derivatives as aurora kinase inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP1382604B1 (en) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20070106549A1 (en) 2005-11-04 2007-05-10 Stocking Christine A Turnkey aviation budget management
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2009140549A1 (en) 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN103254142B (zh) 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104130200B (zh) 2014-07-01 2016-04-20 中山大学 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用
AU2018259078B2 (en) * 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
US11053223B2 (en) 2017-04-27 2021-07-06 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509499A (ja) 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ キナゾリン誘導体およびそれらの医薬品としての使用
US20060178382A1 (en) 2003-06-17 2006-08-10 Astrazeneca Ab Chinazoline derivatives as aurora kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Guo-Wu Rao et al. ChemMedChem. 2013, Vol. 8, pp. 928-933

Also Published As

Publication number Publication date
US20190263787A1 (en) 2019-08-29
US20180312490A1 (en) 2018-11-01
MX389244B (es) 2025-03-20
EP3615522B1 (en) 2021-08-04
JP2020517677A (ja) 2020-06-18
AU2018259078A1 (en) 2019-10-17
KR20190141203A (ko) 2019-12-23
JP7128204B2 (ja) 2022-08-30
AU2018259078B2 (en) 2021-10-07
BR112019022229A2 (pt) 2020-05-12
US10273227B2 (en) 2019-04-30
RU2019136279A (ru) 2021-05-27
TW201904960A (zh) 2019-02-01
CN110573505A (zh) 2019-12-13
EP3615522A1 (en) 2020-03-04
RU2019136279A3 (enExample) 2021-05-31
ES2888298T3 (es) 2022-01-03
MX2019012847A (es) 2022-01-07
CA3059283A1 (en) 2018-11-01
US10829479B2 (en) 2020-11-10
TWI774758B (zh) 2022-08-21
WO2018197642A1 (en) 2018-11-01
CN110573505B (zh) 2023-04-11
AR111494A1 (es) 2019-07-17
RU2769694C2 (ru) 2022-04-05

Similar Documents

Publication Publication Date Title
US10829479B2 (en) C5-anilinoquinazoline compounds and their use in treating cancer
RU2656597C2 (ru) Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста
AU2011311814B2 (en) Substituted pyridazine carboxamide compounds
JP2019518776A (ja) Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶
KR102866403B1 (ko) 카세인 키나아제 1ε 억제제 및 약학 조성물 및 그 응용
KR20170005875A (ko) 1,3,4-티아디아졸 화합물 및 암의 치료에서의 그의 용도
EP3615526B1 (en) Phenoxyquinazoline compounds and their use in treating cancer
Hou et al. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors
CN109810098B (zh) 含有酞嗪-1(2h)-酮结构的parp-1和pi3k双靶点抑制剂
CN116102575A (zh) 环状2-氨基嘧啶类化合物及其用途
BR112019022229B1 (pt) Compostos de anilinoquinazolina c5, composição farmacêutica e uso dos compostos no tratamento do câncer
CN113493436A (zh) 胺基取代吡啶衍生物及其制法和药物组合物与用途
HK1260821B (en) Crystals of aniline pyrimidine compound serving as egfr inhibitor
HK1188216B (en) Substitututed 6-amino-pyridazin-3-yl-carboxamide compounds as protein kinase modulators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210312

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230526

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231030

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231113

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231113

End annual number: 3

Start annual number: 1

PG1601 Publication of registration